Category: Uncategorized

Office Depot Inc. said Monday that it will introduce same-day delivery in three markets in the coming weeks with help from a third-party provider Deliv. The service will launch in Atlanta and Los Angeles on August 28, and in Ft. Lauderdale/Miami on September 6. Office Depot will waive the delivery fee as a limited introductory offer. By the end of 2017, the company expects to add several other markets. Delivery pricing is still being finalized in preparation for the service expansion, according to an Office Depot spokesperson. Office Depot shares are up 31.4% for the year so far while the S&P 500 index is up 10.6% for the period.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Streaming giant Netflix Inc. said on Monday it’s acquired comic book publisher Millarworld, founded by comic book legend Mark Millar. Millar has been responsible for such stories turned films as “Kick-Ass,” “Kingsman” and “Old Man Logan.” Millar also spent eight years at Marvel, where he developed comic books and stories that inspired Walt Disney Co.’s first “Avengers” movie, as well as last year’s hit “Captain America: Civil War.” This is Netflix’s first acquisition and will give the streamer a solid and exclusive portfolio of characters and stories as the company looks to work more closely with filmmakers and acquire intellectual property. Terms of the deal were not disclosed. “Mark has created a next-generation comics universe, full of indelible characters living in situations people around the world can identify easily with,” said Netflix Chief Content Officer Ted Sarandos in a statement. “We look forward to creating new Netflix Originals from several existing franchises as well as new super-hero, anti-hero, fantasy, sci-fi and horror stories Mark and his team will continue to create and publish.” Shares of Netflix have gained nearly 46% in the year to date, while the S&P 500 index is up nearly 11%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Hedge fund Scopia Capital Management LP has boosted its stake in Acorda Therapeutics Inc. to 7.71 million shares from 5.57 million shares, according to recent filings with the Securities and Exchange Commission. Scopia now owns 16.5% of Acorda’s shares outstanding, which would make Scopia Acorda’s largest shareholder, passing Fidelity Management & Research at 14.1% and BlackRock Fund Advisors at 12.7%, according to FactSet. Shares of Acorda, which makes treatments for nervous system disorders, were still inactive in premarket trade. The shares have rallied 14.0% year to date through Friday, while the S&P 500 has gained 10.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

BlackBerry Ltd. stock slid 2.5% in premarket trade Monday, after Goldman Sachs resumed coverage of stock with a sell rating and 10% downside to its $8.50 price target. The stock is trading at a better multiple thanks to an improved balance sheet, the transition from hardware to software and optionality around ADAS (advanced driver assisted systems) software, analyst Gabriela Borges wrote in a note. “However, with the auto business trading at an implied 13-17X revenue, and unlikely to ramp meaningfully until 2019, we think fundamentals will be the primary driver of the stock over the next 12 months,” she wrote. “On this point, we see risk to 2HFY18 and FY19 estimates given the Street modeling a sharp inflection, and increasing competition in EMM (enterprise mobility management.” Shares have gained 37% in 2017, while the S&P 500 has gained 10.6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Analysts at Evercore downgraded shares of Time Warner Inc. to in-line from outperform on Monday, as the stock’s discount relative to AT&T Inc. shares has fallen to about 5% from about 15% at the start of the year. AT&T’s proposed $85.4 billion deal to buy Time Warner is expected to close before year’s end. “We believe the arbitrage spread has compressed enough to warrant a move to the sidelines as the final innings of the deal review approach,” lead analyst Vijay Jayant wrote in a note to investors. Jayant said Time Warner’s fundamentals remain intact through the end of the year following solid second-quarter earnings results last week in which the company reported better-than-expected profit and revenue. Shares of Time Warner have gained more than 6% in the year to date and almost 30% in the previous 12-month period. By comparison, the S&P 500 index is up nearly 11% in the year and more than 13% in the last 12 months.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Mylan NV said early Monday that the Food and Drug Administration has tentatively approved its HIV/AIDS drug combination for patients in developing countries. The combination combines three first-line therapies into a smaller tablet that patients take once a day, Mylan said. The tentative approval was granted under the President’s Emergency Plan for AIDS Relief, which focuses on HIV/AIDS and some other diseases globally. Mylan shares dropped 4.8% in premarket trade Monday. Shares have plummeted 13.1% over the last three months, compared with a 3.2% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Zynerba Pharmaceuticals Inc. shares plummeted 53% premarket on Monday after the company said its mid-stage clinical trial for cannabidiol gel in adult epilepsy with focal seizures didn’t meet its primary endpoint or secondary endpoints. The company is working to evaluate the results and determine next steps. Zynerba Pharma emphasized that the therapy, ZYN002, had a “very favorable safety and tolerability profile,” which was “encouraging” since the company plans to develop ZYN002 for a wide range of conditions. Data for the therapy in osteoarthritis are expected in August, and data from a trial in the genetic condition Fragile X syndrome are expected by the end of September. Company shares have dropped 21.7% over the last three months, compared with a 3.2% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Horizon Pharma PLC shares surged 19% in premarket trade Monday after the company reported second-quarter profit and revenue beats and raised its 2017 revenue guidance. The company said it had a loss of $209.5 million, or a loss of $1.29 per share, after earnings of $15 million, or 9 cents per share in the year-earlier period. Adjusted earnings-per-share were 41 cents, above the FactSet consensus of 10 cents. Revenue rose to $289.5 million from $257.4 million, above the FactSet consensus of $237 million. The latest results included strong performance from the company’s rare disease medicines, Horizon Pharma said. Horizon Pharma also raised its 2017 revenue guidance to $1.01 billion to $1.045 billion from $985 million to $1.02 billion. Company shares have dropped 18.5% over the last three months, compared with a 3.2% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Tyson Foods Inc. reported third-quarter net income of $447.0 million, or $1.21 per share, down from $484.0 million, or $1.25 per share, for the same period last year. Adjusted EPS was $1.28, beating the $1.19 FactSet consensus. Revenue was $9.85 billion, up from $9.40 billion last year and beating the $9.46 billion FactSet consensus. Strong performance in the beef and pork segments are driving investment in the company’s “value-added” chicken and prepared food business, said Tom Hayes, Tyson’s chief executive. The company’s latest acquisition, AdvancePierre, contributed about $100 million in the third quarter and it is expected to contribute $350 million in the fourth quarter. AdvancePierre’s brands include Barber Foods, and the company provides chicken, beef and other products for foodservice purposes. Tyson expects full-year adjusted EPS of $4.95 to $5.05. The FactSet consensus is $5.01. Tyson shares are unchanged in Monday premarket trading, but up 2.6% for the year so far. The S&P 500 index is up 10.6% for 2017 to date.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

MyoKardia Inc. shares surged 31.8% in premarket trade Monday on positive mid-stage clinical trial results for its mavacamten therapy. Patients on the therapy met the trial’s primary endpoint and key secondary endpoints in the phase 2 trial, the company said. MyoKardia expects to start its next clinical trial by the end of this year, depending on discussions with the Food and Drug Administration. The latest data came from the clinical trial’s first patient cohort, in which 11 patients were enrolled and 10 patients completed the study. The one patient in question had a history of atrial fibrillation and experienced an episode of atrial fibrillation during the trial. All other safety problems were mild to moderate, according to MyoKardia, and “a majority of the [adverse events] were deemed to be unrelated to the study drug.” The Independent Data Monitoring Committee reviewed the trial’s safety data and recommended the study be continued, the company said. Mavacamten is intended for symptomatic, obstructive hypertrophic cardiomyopathy, which occurs when heart muscle cells enlarge and block blood flow, and is a common cause of sudden cardiac arrest, according to the American Heart Association. MyoKardia shares have surged 20.4% over the last three months, compared with a 3.2% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News